Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03110926 · ClinicalTrials.gov registry record · Phase 2
Induction Chemotherapy for Locally Advanced Esophageal Cancer
A Phase 2 study of Esophageal Carcinoma, sponsored by University of Rochester.
- Active
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT03110926 is a Phase 2 study of Esophageal Carcinoma that is active but no longer recruiting, run by University of Rochester. The registered enrollment target is 40 participants, below the 2,385-participant average among 17 other Esophageal Carcinoma trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03110926, a Phase 2 study of Esophageal Carcinoma, is active but no longer recruiting, sponsored by University of Rochester.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
Evaluate mFOLFOX6 (5-Fluorouracil, Leucovorin and Oxaliplatin) chemotherapy as induction treatment prior to standard neoadjuvant chemoradiation to decrease the rate of distant recurrence among patients with locally advanced esophageal cancer.
Conditions Studied
Interventions
- COMBINATION_PRODUCT Chemoradiation
- DRUG mFOLFOX6
Study Locations (1)
New York
- University of Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2017-06-19 |
| Est. Completion | 2027-05-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03110926
The ClinicalTrials.gov registry entry for NCT03110926 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,385-participant average among 17 other Esophageal Carcinoma trials with a reported enrollment target (98% lower). The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Esophageal Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Chemoradiation is the first listed.
NCT03110926 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT03110926 about?
NCT03110926 is a clinical study titled "Induction Chemotherapy for Locally Advanced Esophageal Cancer". Evaluate mFOLFOX6 (5-Fluorouracil, Leucovorin and Oxaliplatin) chemotherapy as induction treatment prior to standard neoadjuvant chemoradiation to decrease the rate of distant recurrence among patients with locally advanced esophageal cancer.
What is the current status of trial NCT03110926?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2017-06-19. Estimated completion is 2027-05-31.
What conditions does trial NCT03110926 study?
This clinical trial studies the following conditions: Esophageal Carcinoma.
What interventions are being tested in trial NCT03110926?
The interventions under investigation include: Chemoradiation (COMBINATION_PRODUCT), mFOLFOX6 (DRUG).
Who is sponsoring clinical trial NCT03110926?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03110926 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Esophageal Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer
RECRUITING · Phase 2
-
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
RECRUITING · Phase 2
-
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
ACTIVE NOT RECRUITING · Phase 2
-
Phase II Trial of Preoperative Combined Modality Therapy for Esophageal Carcinoma: Cisplatin-Irinotecan Followed by Radiation Therapy With Concurrent Cisplatin and Irinotecan.
COMPLETED · Phase 2
-
Dyadic Yoga Intervention in Improving Physical Performance and Quality of Life in Patients With Stage I-IV Non-small Cell Lung or Esophageal Cancer Undergoing Radiotherapy and Their Caregivers
RECRUITING · NA
-
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.